MRSA or Methicillin-resistant Saphylococcus areus is a bacterial skin infection that has become hard to treat as it has developed a resistance to most antibiotics. The disease can easily be life-threatening and is unfortunately found in medical centers.
A new drug has been approved by the U.S. Food and Drug Administration called Dalvance. Dalvance is the first drug to be labeled as a Qualified Infectious Disease Product (QIDP) by the FDA. This and any drug labeled under the QIDP category will be put on priority and expedited review process. The drug will also qualify for five extra years of marketing exclusivity.
The QIPD category was created in order to encourage the creation of other drugs like it in order to treat other antibiotic-resistant infections. Such infections are a real threat to today’s medical science. It really isn’t much of a stretch to say that there may come a time when typical antibiotics will no longer work. Hopefully, more drugs like Dalvance will come into the market at a quicker rate.
See full story at cnn.com